在JAK2-突变多细胞血症维拉和基本血栓血症中,血栓形成驱动的疾病进展:重新评估基于风险的管理
Tiziano Barbui1, Valerio De Stefano2,3, Elena Rossi2,3
1FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy.
American journal of hematology
|March 10, 2025
概括
针对真多细胞血症和精性血小板血症的新兴疗法向炎症和血栓形成. 早期干预可以预防疾病的进展,并改善这些骨髓增殖性瘤的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 真菌多细胞血症和基本血栓细胞血症是骨髓增殖性瘤,其特征是血液细胞数量增加.
- 血栓形成是一个主要的并发症,导致疾病进展到骨髓纤维化,爆发期,二次癌症和死亡率.
- JAK2 V617F突变与病变发生有关,促进炎症.
研究的目的:
- 探索针对真多细胞血症和精性血栓细胞血症的新兴疗法.
- 突出血栓瘤作为疾病进展的驱动因素的作用.
- 讨论炎症,血栓形成和疾病并发症之间的相互作用.
主要方法:
- 关于新兴疗法的当前文献的综述.
- 分析JAK2 V617F突变在病变发生中的作用.
- 讨论将血栓和炎症联系在一起的致病机制.
主要成果:
- 高风险患者的血栓形成率有所下降,但低风险患者的血栓形成率仍然很高,主要是动脉.
- 动脉血栓症可能会延续炎症循环,加速疾病并发症.
- 新兴的疗法旨在解决细胞减少和炎症.
结论:
- 早期干预细胞减小剂和抗炎剂至关重要.
- 向由血栓形成驱动的炎症回路可能会防止疾病的进展.
- 新的治疗策略有望改善多细胞真血症和精髓血栓塞瘤的治疗结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
Disorders of Hemostasis
676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Esophageal Varices-II: Clinical Features and Management
34
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
34
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
122
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
122


